FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1913812445> ?p ?o ?g. }

• W1913812445 endingPage "77" @default.
• W1913812445 startingPage "71" @default.
• W1913812445 abstract "Aims In September 1995, the indication for the oral dopamine agonist ibopamine was restricted in the Netherlands and in several other European countries to patients with NYHA‐class II heart failure as a result of an interim analysis of the PRIME‐II trial. This trial demonstrated an increased risk of mortality in patients with NYHA‐class III/IV heart failure on ibopamine. In September 1995, we initiated an assessment of the effects of ibopamine under everyday circumstances in a cohort of users of ibopamine in all NYHA‐classes. Methods In a nationwide retrospective cohort study all 2147 community pharmacies and drug dispensing general practitioners received a request to list all patients to whom they had dispensed ibopamine in the preceding years. All responding drug dispensing outlets (DDO) received a questionnaire on cardiovascular risk factors and mortality for the general practitioner of a random sample of these patients. DDO were also requested to send an anonymised printout of the complete medication record. On the end‐date of follow‐up, February 15th 1996, mortality rates were compared across categories of ibopamine use, adjusted for potential confounders. To assess medication use, drug exposure was compared in a 3 months’ period before date of death in the deceased, and before a random date in those patients who were still alive. Results In patients with NYHA‐class III/IV heart failure, multivariate analysis indicated that current use of ibopamine was significantly associated with mortality (RR 1.37;95% CI: 1.15–1.64). In patients with NYHA‐class I/II heart failure, however, multivariate analysis showed a 2.03 (95% CI: 1.10–3.72) risk of mortality in current users of ibopamine. Apart from current use of ibopamine, male gender and increased serum creatinine were also independent risk factors for mortality in all NYHA‐classes. No statistically significant association was found between mortality and current use of amiodarone or use of amiodarone at baseline. Conclusions The increased risk of mortality in patients with NYHA‐class III and IV heart failure on ibopamine seems to confirm the main finding of the recently published PRIME‐II trial. However, our results indicate that also patients with NYHA‐class I/II heart failure may be at an increased risk of mortality when using ibopamine. Additional research on the effects of ibopamine in these patients is warranted and the use of ibopamine in NYHA‐class II heart failure patients may have to be reconsidered." @default.
• W1913812445 created "2016-06-24" @default.
• W1913812445 creator A5007319489 @default.
• W1913812445 creator A5007679161 @default.
• W1913812445 creator A5019888765 @default.
• W1913812445 creator A5047304335 @default.
• W1913812445 creator A5047331394 @default.
• W1913812445 date "1998-07-01" @default.
• W1913812445 modified "2023-10-14" @default.
• W1913812445 title "Risk factors for mortality in users of ibopamine" @default.
• W1913812445 cites W123436534 @default.
• W1913812445 cites W1971771549 @default.
• W1913812445 cites W1994239059 @default.
• W1913812445 cites W2003563571 @default.
• W1913812445 cites W2014702816 @default.
• W1913812445 cites W2015570306 @default.
• W1913812445 cites W2018338876 @default.
• W1913812445 cites W2030493333 @default.
• W1913812445 cites W2043935684 @default.
• W1913812445 cites W2054577589 @default.
• W1913812445 cites W2065266129 @default.
• W1913812445 cites W2091079914 @default.
• W1913812445 cites W2096105382 @default.
• W1913812445 cites W2099178324 @default.
• W1913812445 cites W2111936495 @default.
• W1913812445 cites W2113865982 @default.
• W1913812445 cites W2319534362 @default.
• W1913812445 cites W2336310974 @default.
• W1913812445 cites W80481722 @default.
• W1913812445 doi "https://doi.org/10.1046/j.1365-2125.1998.00046.x" @default.
• W1913812445 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1873974" @default.
• W1913812445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9690952" @default.
• W1913812445 hasPublicationYear "1998" @default.
• W1913812445 type Work @default.
• W1913812445 sameAs 1913812445 @default.
• W1913812445 citedByCount "13" @default.
• W1913812445 countsByYear W19138124452012 @default.
• W1913812445 countsByYear W19138124452017 @default.
• W1913812445 countsByYear W19138124452019 @default.
• W1913812445 crossrefType "journal-article" @default.
• W1913812445 hasAuthorship W1913812445A5007319489 @default.
• W1913812445 hasAuthorship W1913812445A5007679161 @default.
• W1913812445 hasAuthorship W1913812445A5019888765 @default.
• W1913812445 hasAuthorship W1913812445A5047304335 @default.
• W1913812445 hasAuthorship W1913812445A5047331394 @default.
• W1913812445 hasBestOaLocation W19138124451 @default.
• W1913812445 hasConcept C126322002 @default.
• W1913812445 hasConcept C166957645 @default.
• W1913812445 hasConcept C168563851 @default.
• W1913812445 hasConcept C194828623 @default.
• W1913812445 hasConcept C201903717 @default.
• W1913812445 hasConcept C2776957806 @default.
• W1913812445 hasConcept C2778198053 @default.
• W1913812445 hasConcept C61943457 @default.
• W1913812445 hasConcept C71924100 @default.
• W1913812445 hasConcept C72563966 @default.
• W1913812445 hasConcept C77350462 @default.
• W1913812445 hasConcept C95457728 @default.
• W1913812445 hasConceptScore W1913812445C126322002 @default.
• W1913812445 hasConceptScore W1913812445C166957645 @default.
• W1913812445 hasConceptScore W1913812445C168563851 @default.
• W1913812445 hasConceptScore W1913812445C194828623 @default.
• W1913812445 hasConceptScore W1913812445C201903717 @default.
• W1913812445 hasConceptScore W1913812445C2776957806 @default.
• W1913812445 hasConceptScore W1913812445C2778198053 @default.
• W1913812445 hasConceptScore W1913812445C61943457 @default.
• W1913812445 hasConceptScore W1913812445C71924100 @default.
• W1913812445 hasConceptScore W1913812445C72563966 @default.
• W1913812445 hasConceptScore W1913812445C77350462 @default.
• W1913812445 hasConceptScore W1913812445C95457728 @default.
• W1913812445 hasIssue "1" @default.
• W1913812445 hasLocation W19138124451 @default.
• W1913812445 hasLocation W19138124452 @default.
• W1913812445 hasLocation W19138124453 @default.
• W1913812445 hasLocation W19138124454 @default.
• W1913812445 hasOpenAccess W1913812445 @default.
• W1913812445 hasPrimaryLocation W19138124451 @default.
• W1913812445 hasRelatedWork W1987071845 @default.
• W1913812445 hasRelatedWork W2013188809 @default.
• W1913812445 hasRelatedWork W2079014624 @default.
• W1913812445 hasRelatedWork W2102471993 @default.
• W1913812445 hasRelatedWork W2332897556 @default.
• W1913812445 hasRelatedWork W2756885576 @default.
• W1913812445 hasRelatedWork W3043104211 @default.
• W1913812445 hasRelatedWork W3206855180 @default.
• W1913812445 hasRelatedWork W4236719168 @default.
• W1913812445 hasRelatedWork W605648234 @default.
• W1913812445 hasVolume "46" @default.
• W1913812445 isParatext "false" @default.
• W1913812445 isRetracted "false" @default.
• W1913812445 magId "1913812445" @default.
• W1913812445 workType "article" @default.